Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1
ACS Infectious Diseases · 2024
DOI: 10.1021/acsinfecdis.4c00232 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Infectious Diseases, 2024. Verfasst von Jennifer E Collins und 13 weiteren Autor:innen. Beteiligte Einrichtung: Division of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, 12722 Research Parkway, Orlando, Florida 32…. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Toxoplasma, Drug Resistance. Die Arbeit nennt 44 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, U.S. Department of Health and Human Services, Bill and Melinda Gates Foundation.
Abstract (Originalsprache)
Our previous work identified a series of 12 xanthoquinodin analogues and 2 emodin-dianthrones with broad-spectrum activities against Trichomonas vaginalis, Mycoplasma genitalium, Cryptosporidium parvum, and Plasmodium falciparum. Analyses conducted in this study revealed that the most active analogue, xanthoquinodin A1, also inhibits Toxoplasma gondii tachyzoites and the liver stage of Plasmodium berghei, with no cross-resistance to the known antimalarial targets PfACS, PfCARL, PfPI4K, or DHODH. In Plasmodium, inhibition occurs prior to multinucleation and induces parasite death following 12 h of compound exposure. This moderately fast activity has impeded resistance line generation, with xanthoquinodin A1 demonstrating an irresistible phenotype in both T. gondii and P. falciparum.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Molecular Microbiology, Burnett School of Biomedical Sciences, University of Central Florida, 12722 Research Parkway, Orlando, Florida 32826, United States.
- Department of Pediatrics, School of Medicine, University of California San Diego, La Jolla, California 92093, United States.
- College of Pharmacy, Duksung Women's University, Seoul 01369, Republic of Korea.
- Department of Chemistry and Biochemistry, Institute for Natural Products Applications & Research Technologies, University of Oklahoma, 101 Stephenson Parkway, Norman, Oklahoma 73019, United States.
- Department of Microbiology and Immunology, Columbia University Irving Medical Center, New York, New York 10032, United States.
ORCID-Profile: Jin Woo Lee, Raphaella Paes, Natalia Mojica Santos, Robert H Cichewicz, Elizabeth A Winzeler, Debopam Chakrabarti
Förderung
- NIAID NIH HHS
- U.S. Department of Health and Human Services
- Bill and Melinda Gates Foundation
Zitieren
APA
Collins, J. E., Jiang, T., Lee, J. W., Wendt, K., Nardella, F., Jeon, J., Paes, R., Santos, N. M., Rocamora, F., Chang, M., Schaefer, S., Cichewicz, R. H., Winzeler, E. A., & Chakrabarti, D. (2024). Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1. ACS Infectious Diseases. https://doi.org/10.1021/acsinfecdis.4c00232
Vancouver
Collins JE, Jiang T, Lee JW, Wendt K, Nardella F, Jeon J, et al. Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1. ACS Infectious Diseases. 2024. doi:10.1021/acsinfecdis.4c00232
BibTeX
@article{Collins2024,
author = {Collins, Jennifer E and Jiang, Tiantian and Lee, Jin Woo and Wendt, Karen and Nardella, Flore and Jeon, Jin and Paes, Raphaella and Santos, Natalia Mojica and Rocamora, Frances and Chang, Maya and Schaefer, Samuel and Cichewicz, Robert H and Winzeler, Elizabeth A and Chakrabarti, Debopam},
title = {Understanding the Antiplasmodial Action of Resistance-Refractory Xanthoquinodin A1},
journal = {ACS Infectious Diseases},
year = {2024},
doi = {10.1021/acsinfecdis.4c00232}
}
EUVIMED